NASDAQ:CGEN - Compugen Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.39 -0.08 (-1.46 %) (As of 12/5/2019 04:00 PM ET) Add Compare Today's Range$5.30Now: $5.39▼$5.4750-Day Range$3.89MA: $5.16▼$6.0952-Week Range$2.00Now: $5.39▼$6.22Volume133,861 shsAverage Volume178,708 shsMarket Capitalization$276.47 millionP/E RatioN/ADividend YieldN/ABeta2.73 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CGEN Previous Symbol CUSIPN/A CIK1119774 Webhttp://www.cgen.com/ Phone972-3765-8585Debt Debt-to-Equity Ratio0.07 Current Ratio7.19 Quick Ratio7.19Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$17.80 million Price / Sales15.53 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book7.38Profitability EPS (Most Recent Fiscal Year)($0.41) Net Income$-22,600,000.00 Net MarginsN/A Return on Equity-83.99% Return on Assets-57.76%Miscellaneous Employees89 Outstanding Shares51,293,000Market Cap$276.47 million Next Earnings Date2/25/2020 (Estimated) OptionableOptionable Receive CGEN News and Ratings via Email Sign-up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CGEN Rates by TradingView Compugen (NASDAQ:CGEN) Frequently Asked Questions What is Compugen's stock symbol? Compugen trades on the NASDAQ under the ticker symbol "CGEN." How were Compugen's earnings last quarter? Compugen Ltd. (NASDAQ:CGEN) posted its quarterly earnings data on Monday, November, 11th. The biotechnology company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.01. View Compugen's Earnings History. When is Compugen's next earnings date? Compugen is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Compugen. What price target have analysts set for CGEN? 1 Wall Street analysts have issued 12-month price objectives for Compugen's shares. Their forecasts range from $9.00 to $9.00. On average, they anticipate Compugen's share price to reach $9.00 in the next year. This suggests a possible upside of 67.0% from the stock's current price. View Analyst Price Targets for Compugen. What is the consensus analysts' recommendation for Compugen? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Compugen. Has Compugen been receiving favorable news coverage? News stories about CGEN stock have trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Compugen earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Compugen. Who are some of Compugen's key competitors? Some companies that are related to Compugen include Orchard Therapeutics (ORTX), Fate Therapeutics (FATE), Krystal Biotech (KRYS), SpringWorks Therapeutics (SWTX), NanoString Technologies (NSTG), Precision BioSciences (DTIL), Aerie Pharmaceuticals (AERI), Vericel (VCEL), BAVARIAN NORDIC/S (BVNRY), Atara Biotherapeutics (ATRA), Twist Bioscience (TWST), MeiraGTx (MGTX), Rubius Therapeutics (RUBY), DBV TECHNOLOGIE/S (DBVT) and Cortexyme (CRTX). What other stocks do shareholders of Compugen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), Sarepta Therapeutics (SRPT), Pluristem Therapeutics (PSTI), Catalyst Pharmaceuticals (CPRX), Sorrento Therapeutics (SRNE), Protalix Biotherapeutics (PLX), Novavax (NVAX), REDHILL BIOPHAR/S (RDHL) and Amarin (AMRN). Who are Compugen's key executives? Compugen's management team includes the folowing people: Dr. Anat Cohen-Dayag, CEO, Pres & Director (Age 52)Mr. Ari Krashin, Chief Financial & Operating Officer (Age 46)Dr. John J. Hunter Ph.D., Chief Scientific Officer (Age 56)Mr. Kirk A. Christoffersen, Sr. VP of Corp. & Bus. Devel. (Age 50)Dr. Zurit Levine, Sr. VP of Technology Innovation (Age 51) Who are Compugen's major shareholders? Compugen's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Nikko Asset Management Americas Inc. (15.26%), Taylor Frigon Capital Management LLC (1.46%), Rothschild Investment Corp IL (0.65%), Defender Capital LLC. (0.58%), Phoenix Holdings Ltd. (0.11%) and Benjamin F. Edwards & Company Inc. (0.07%). Which institutional investors are selling Compugen stock? CGEN stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Benjamin F. Edwards & Company Inc., Rothschild Investment Corp IL, Taylor Frigon Capital Management LLC and Defender Capital LLC.. Which institutional investors are buying Compugen stock? CGEN stock was bought by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Phoenix Holdings Ltd., State Street Corp and Janney Montgomery Scott LLC. How do I buy shares of Compugen? Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Compugen's stock price today? One share of CGEN stock can currently be purchased for approximately $5.39. How big of a company is Compugen? Compugen has a market capitalization of $276.47 million and generates $17.80 million in revenue each year. The biotechnology company earns $-22,600,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis. Compugen employs 89 workers across the globe.View Additional Information About Compugen. What is Compugen's official website? The official website for Compugen is http://www.cgen.com/. How can I contact Compugen? Compugen's mailing address is AZRIELI CENTER 26 HAROKMIM STREET BUILDING D, HOLON L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected] MarketBeat Community Rating for Compugen (NASDAQ CGEN)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 251 (Vote Outperform)Underperform Votes: 233 (Vote Underperform)Total Votes: 484MarketBeat's community ratings are surveys of what our community members think about Compugen and other stocks. Vote "Outperform" if you believe CGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/5/2019 by MarketBeat.com StaffFeatured Article: What are municipal bonds?
